319 related articles for article (PubMed ID: 24566710)
1. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
Shayani S; Palmer J; Stiller T; Liu X; Thomas SH; Khuu T; Parker PM; Khaled SK; Forman SJ; Nakamura R
Biol Blood Marrow Transplant; 2013 Feb; 19(2):298-304. PubMed ID: 23078784
[TBL] [Abstract][Full Text] [Related]
4. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.
Rosenthal J; Pawlowska A; Bolotin E; Cervantes C; Maroongroge S; Thomas SH; Forman SJ
Pediatr Blood Cancer; 2011 Jul; 57(1):142-6. PubMed ID: 21557459
[TBL] [Abstract][Full Text] [Related]
5. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
[TBL] [Abstract][Full Text] [Related]
6. Intrapatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy.
Sagou K; Fukushima N; Ukai S; Goto M; Ozeki K; Kohno A
Int J Hematol; 2021 Jan; 113(1):63-72. PubMed ID: 32876853
[TBL] [Abstract][Full Text] [Related]
7. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
García-Martín P; Alarcón-Payer C; López-Fernández E; Moratalla L; Romero A; Sainz J; Ríos R; Jurado M
Ann Pharmacother; 2015 Sep; 49(9):986-94. PubMed ID: 26160968
[TBL] [Abstract][Full Text] [Related]
8. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.
Khimani F; Kim J; Chen L; Dean E; Rizk V; Betts B; Nishihori T; Locke F; Mishra A; Perez L; Ayala E; Kharfan-Dabaja M; Nieder M; Fernandez H; Anasetti C; Pidala J
Bone Marrow Transplant; 2017 Jul; 52(7):1003-1009. PubMed ID: 28368376
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
12. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA
Bone Marrow Transplant; 2017 Mar; 52(3):438-444. PubMed ID: 27819684
[TBL] [Abstract][Full Text] [Related]
14. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
17. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.
Elfeky R; Lucchini G; Lum SH; Ottaviano G; Builes N; Nademi Z; Battersby A; Flood T; Owens S; Cant AJ; Young H; Greener S; Walsh P; Kavanagh D; Annavarapu S; Rao K; Amrolia P; Chiesa R; Worth A; Booth C; Skinner R; Doncheva B; Standing J; Gennery AR; Qasim W; Slatter M; Veys P
Blood Adv; 2020 Jun; 4(11):2418-2429. PubMed ID: 32492158
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review].
Han W; Han Y; Chen J; Ma X; Chen F; Wu XJ; Qi JQ; Qiu HY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):666-70. PubMed ID: 27587247
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]